Although significant advances have been made in the past 30 years in the understanding of HIV pathogenesis, there is still a need for development of effective antiretroviral therapy for the long-term management of HIV infection in infants, children and adults, as well as antiretroviral interventions to prevent HIV in women, who have the greatest burden of HIV in sub-Saharan Africa, children, in discordant couples, men who have sex with men and certain high risk heterosexual populations. With 1.9 million people receiving antiretroviral therapy in South Africa alone, further clinical problems related to durability of therapy, viral resistance and adverse events are emerging. Moreover, male circumcision, access to voluntary counseling and HIV testing, male and female condoms and other behavioral interventions are important components of governments'strategies to control HIV, new HIV Infections remain persistently high. Biomedical interventions are urgently required especially to protect women. Without an effective HIV vaccine, it is doubtful whether eradication of the HIV infection is feasible. TB/HIV co-infection adds significant morbidity and mortality to HIV infected infants, children and adults, and is the leading cause of death in South Africa. More potent, shorter and less toxic treatment for TB, to prevent TB, and to treat drug resistant TB are desperately needed. Our proposed KAREBELO CTU, comprises a group of internationally renowned scientists, the majority of whom are based in South Africa, are women, and come from diverse racial and ethnic backgrounds. Our eight Clinical Research Sites forming the KARABELO Clinical Trials Unit (CTU) are strategically positioned in areas of high HIV prevalence and Incidence and include informal settlements, maternity units, TB clinics and an MDR hospital, cities and migrant laborers to answer critical questions in the control and prevention of both HIV and TB. The CRSs, seven of which are in South Africa and one in Long Island, New York have capacity to address critical clinical research agendas of four selected NIAID Clinical Research networks: vaccines to prevent HIV infection;microbicides to prevent HIV infection;HIV/AIDS and HIV-associated infections in infants and maternal populations;and therapeutics for HIV/AIDS and HIV-associated infections and pathogens in adults.

Public Health Relevance

HIV and TB continue to be one of greatest threats to human health. Progress in understanding and managing HIV, although revolutionary, and translated into practice at an advanced rate, has not yet yielded an effective HIV vaccine, microbicide or cure. Similarly, despite advancements in TB management, an effective vaccine for TB remains elusive.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069453-08
Application #
8609241
Study Section
Special Emphasis Panel (ZAI1-JBS-A (S2))
Program Officer
Potter, Dara G
Project Start
2007-02-15
Project End
2020-11-30
Budget Start
2013-12-10
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$2,414,717
Indirect Cost
$185,764
Name
Wits Health Consortium (Pty), Ltd
Department
Type
DUNS #
639391218
City
Johannesburg
State
Country
South Africa
Zip Code
Riddler, Sharon A; Husnik, Marla; Ramjee, Gita et al. (2017) HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One 12:e0178594
Bekker, Linda-Gail; Gray, Glenda E (2017) Hope for HIV control in southern Africa: The continued quest for a vaccine. PLoS Med 14:e1002241
Corey, Lawrence; Gray, Glenda E (2017) Preventing acquisition of HIV is the only path to an AIDS-free generation. Proc Natl Acad Sci U S A 114:3798-3800
Eshleman, Susan H; Hudelson, Sarah E; Redd, Andrew D et al. (2017) Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 74:112-116
Brahmbhatt, Heena; Boivin, Michael; Ssempijja, Victor et al. (2017) Impact of HIV and Atiretroviral Therapy on Neurocognitive Outcomes Among School-Aged Children. J Acquir Immune Defic Syndr 75:1-8
Boeree, Martin J; Heinrich, Norbert; Aarnoutse, Rob et al. (2017) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 17:39-49
Murnane, Pamela M; Sigamoney, Stacy-Lee; Pinillos, Francoise et al. (2017) Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care 29:378-386
Palumbo, Philip J; Wilson, Ethan A; Piwowar-Manning, Estelle et al. (2017) Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One 12:e0177281
Wall, Kristin M; Rida, Wasima; Haddad, Lisa B et al. (2017) Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries. Epidemiology 28:224-232
Fogel, Jessica M; Clarke, William; Kulich, Michal et al. (2017) Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043). J Acquir Immune Defic Syndr 74:158-165

Showing the most recent 10 out of 45 publications